Creative Medical Technology Holdings Inc. (CELZ) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
211 E. OSBORN RD. PHOENIX, AZ 85012 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 9/30/2024 MRQ | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 3,467 | 18,399 | 10,724 | 98 | 89 | 304 | |||
| Cash and cash equivalents | 3,467 | 18,399 | 10,724 | 98 | 89 | 304 | |||
| Receivables | 6 | 10 | |||||||
| Inventory, net of allowances, customer advances and progress billings | 7 | 10 | 11 | ||||||
| Inventory | 7 | 10 | 11 | ||||||
| Other undisclosed current assets | 6,797 | 338 | 2 | ||||||
| Total current assets: | 10,271 | 18,747 | 10,737 | 98 | 94 | 314 | |||
| Noncurrent Assets | |||||||||
| Intangible assets, net (including goodwill) | 441 | 436 | 528 | 620 | 437 | 164 | |||
| Intangible assets, net (excluding goodwill) | 441 | 436 | 528 | 620 | 437 | 164 | |||
| Other undisclosed noncurrent assets | 3 | 3 | 3 | ||||||
| Total noncurrent assets: | 444 | 439 | 531 | 620 | 437 | 164 | |||
| TOTAL ASSETS: | 10,715 | 19,186 | 11,268 | 718 | 531 | 477 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 357 | 3,307 | 786 | 511 | 441 | 353 | |||
| Accounts payable | 317 | 3,268 | 762 | 351 | 321 | 332 | |||
| Accrued liabilities | 40 | 40 | 24 | 160 | 120 | 22 | |||
| Debt | 789 | 1,062 | 682 | ||||||
| Derivative instruments and hedges, liabilities | 38,742 | 6,848 | 3,227 | ||||||
| Due to related parties | ✕ | ✕ | 14 | 14 | 11 | 11 | 11 | ||
| Other undisclosed current liabilities | 14 | 250 | 469 | 240 | 198 | ||||
| Total current liabilities: | 371 | 3,322 | 1,050 | 40,521 | 8,602 | 4,472 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 371 | 3,322 | 1,050 | 40,521 | 8,602 | 4,472 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 10,344 | 15,865 | 10,218 | (39,803) | (8,071) | (3,995) | |||
| Common stock | 1 | 14 | 6 | 769 | 22 | 903 | |||
| Treasury stock, value | (271) | ||||||||
| Additional paid in capital | 69,712 | 69,662 | 53,879 | 21,316 | 17,468 | 12,181 | |||
| Accumulated deficit | (59,098) | (53,812) | (43,668) | (61,890) | (25,565) | (17,081) | |||
| Other undisclosed equity, attributable to parent | 3 | 3 | 3 | ||||||
| Total equity: | 10,344 | 15,865 | 10,218 | (39,803) | (8,071) | (3,995) | |||
| TOTAL LIABILITIES AND EQUITY: | 10,715 | 19,186 | 11,268 | 718 | 531 | 477 | |||
Income Statement (P&L) ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 9 | 89 | 88 | 165 | 166 | 124 | ||
| Other income | 100 | |||||||
| Cost of revenue | (4) | (28) | (48) | (51) | (45) | (70) | ||
| Gross profit: | 5 | 60 | 40 | 114 | 120 | 54 | ||
| Operating expenses | (5,626) | (10,304) | (3,166) | (1,229) | (1,250) | (1,168) | ||
| Operating loss: | (5,620) | (10,244) | (3,126) | (1,115) | (1,130) | (1,114) | ||
| Nonoperating income (expense) | 334 | 100 | 22,338 | (35,210) | (7,354) | (12,541) | ||
| Interest and debt expense | 586 | (1,230) | (366) | 408 | ||||
| Income (loss) from continuing operations before equity method investments, income taxes: | (5,287) | (10,144) | 19,797 | (37,555) | (8,850) | (13,247) | ||
| Other undisclosed income (loss) from continuing operations before income taxes | (586) | 1,230 | 366 | (408) | ||||
| Income (loss) from continuing operations: | (5,287) | (10,144) | 19,212 | (36,325) | (8,484) | (13,656) | ||
| Income (loss) before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | 19,212 | (36,325) | (8,484) | (13,656) | |
| Net income (loss) attributable to parent: | (5,287) | (10,144) | 19,212 | (36,325) | (8,484) | (13,656) | ||
| Preferred stock dividends and other adjustments | (197) | |||||||
| Other undisclosed net income available to common stockholders, basic | 197 | |||||||
| Net income (loss) available to common stockholders, basic: | (5,287) | (10,144) | 19,212 | (36,325) | (8,484) | (13,656) | ||
| Other undisclosed net loss available to common stockholders, diluted | (989) | |||||||
| Net income (loss) available to common stockholders, diluted: | (5,287) | (10,144) | 18,222 | (36,325) | (8,484) | (13,656) | ||
Comprehensive Income ($ in thousands)
| 9/30/2024 TTM | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (5,287) | (10,144) | 19,212 | (36,325) | (8,484) | (13,656) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (5,287) | (10,144) | 19,212 | (36,325) | (8,484) | (13,656) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.